AstraZeneca got a new breast cancer approval and reported strong Phase 3 data, which supports future product sales and development momentum.
AstraZeneca secured regulatory approval for a new breast cancer drug and reported strong Phase 3 trial data. Those clinical wins point toward more product momentum and clearer commercialization paths for AstraZeneca.
Leidos reported better-than-expected second-quarter results and raised its FY26 guidance, which signals stronger near-term revenue and profit trends.
Expeditors posted better-than-expected second-quarter earnings and sales, which indicates stronger freight volumes and pricing versus estimates.
Follow AstraZeneca PLC (AZN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AZN